Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 4 and 12 Months of Age

Trial Profile

Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 4 and 12 Months of Age

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2014

At a glance

  • Drugs GSK 2202083A (Primary) ; Hib-DTaP-hepatitis B-poliovirus vaccine; Meningococcal vaccine group C conjugate; Pneumococcal 13-valent CRM197 vaccine conjugate; RIX 4414
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Meningococcal group C infections; Neisseria infections; Pertussis; Pneumococcal infections; Poliomyelitis; Rotavirus infections; Tetanus
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 28 Oct 2011 Actual end date added (Oct 2011) as reported by ClinicalTrials.gov.
    • 28 Oct 2011 Actual patient number is 480 as reported by ClinicalTrials.gov.
    • 28 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top